NFE2L2和MYC基因相对拷贝数在肺癌诊断中的临床价值分析

Clinical value analysis of relative copy number of NFE2L2 and MYC genes in the diagnosis of lung cancer

目的探究肺癌患者NFE2L2和MYC基因相对拷贝数的变化,并初步探讨其对肺癌的诊断价值。方法研究纳入2021年9月~2023年6月在我院住院的36例肺癌患者,采用实时荧光定量PCR方法检测肿瘤组织和邻近非肿瘤组织样本中的NFE2L2和MYC基因相对拷贝数,使用受试者工作特征(ROC)曲线评估诊断性能。结果肿瘤组织样本NFE2L2和MYC基因相对拷贝数高于非肿瘤组织样本,差异有统计学意义(P<0.05)。ROC曲线分析显示,NFE2L2和MYC基因相对拷贝数是较好的肺癌诊断指标(AUC=0.765、0.761)。结论NFE2L2和MYC基因相对拷贝数可能与肺癌的发生有关,对肺癌的诊断具有一定参考价值。

Objective To investigate the changes of relative copy number of NFE2L2 and MYC genes in lung cancer patients,and to preliminarily explore their diagnostic value for lung cancer.Methods A total of 36 patients with lung cancer who were hospitalized in our hospital from September 2021 to June 2023 were enrolled in the study.The relative copy numbers of NFE2L2 and MYC genes in tumor tissue and adjacent non-tumor tissue samples were detected by real-time fluorescence quantitative PCR,and the diagnostic performance was evaluated by receiver operating characteristic(ROC)curve.Results The relative copy number of NFE2L2 and MYC genes in tumor tissue samples was higher than that in non-tumor tissue samples,and the difference was statistically significant(P<0.05).ROC curve analysis showed that the relative copy number of NFE2L2 and MYC genes were good diagnostic index for lung cancer(AUC=0.765,0.761).Conclusion The relative copy number of the NFE2L2 and MYC genes may be related to the occurrence of lung cancer,which has certain reference value for the diagnosis of lung cancer.